Articles On Starpharma Holdings (ASX:SPL)

Starpharma Holdings Limited (ASX: SPL) shares are having a mixed morning after the Aussie healthcare group’s latest quarterly update. The Starpharma share price opened today’s session 5.88% higher at $1.80. However, since then, the company...

Summary Drug discovery company developing new therapies, Dimerix, has enrolled multiple patients in REMAP-CAP study in Europe. In the ACE2 RAS study domain, subjects will be randomised to receive one RAS blockade strategy or control....

While the Starpharma Holdings Limited (ASX: SPL) share price is having a reasonable day today – up 0.77%, it’s done very well so far in 2021. At the time of writing, shares in the pharmaceutical company are trading for $1.96 cents each. Wh...

Uranium explorer 92 Energy (ASX:92E) is among several companies lined up to list on the ASX this or next week after bioenergy company Delorean joined the bourse yesterday. There are four IPOs timed for this week, including Delorean (ASX: DE...

The Starpharma Holdings Limited (ASX: SPL) share price has come under pressure on Tuesday despite the release of a positive announcement. In afternoon trade, the dendrimer products developer’s shares are down 4.5% to $1.99. What did Starph...

Source: Source: janews , Shutterstock   Healthcare takes over 1/10th per cent of the GDP of the most developed countries and the US contributes the most to this industry. As the coronavirus pandemic hit hard every industry, including hea...

It's been a rocky month of trading for Starpharma Holdings Ltd [ASX:SPL] investors. The ASX SPL share price hitting a low point of $1.77 two weeks ago, only to now rebound back to $2.14 last Monday... The post Starpharma Shares Down Despite...

25 Mar 2021 - Starpharma (ASX: SPL) signs an agreement with Lloyds Pharmacy in the UK for the distribution of its VIRALEZE antiviral nasal spray.

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher on Thursday morning. At the time of writing, the dendrimer products developer’s shares are up 3.5% to $2.10. Why is the Starpharma share price pushing higher? Investo...

Global stock markets dipped Stock markets dipped globally on fears over a potential third lockdown in Europe. Wall Street has seesawed throughout the week, as European shares hit a two-week low. Dow Jones was down 0.01%, S&P 500 fell by...

Pharmaceuticals manufacturer Starpharma (ASX: SPL) will commence the rollout of its COVID-killing nasal spray in the UK after signing a deal with a major pharmacy chain. The group's antiviral nasal spray called VIRALEZE will be stocked by...

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher on Tuesday morning. At one stage today, the dendrimer products developer’s shares were up as much as 6% to $1.98. At the time of writing, Starpharma share price has e...

16 Mar 2021 - Starpharma (ASX:SPL) says its second radiopharmaceutical candidate, DEP HER2-lutetium, achieved potent and durable anticancer activity, with complete tumour regressio…

During February the ASX200 recorded a fifth consecutive monthly rise with the materials and financial sectors leading the way. -The ASX200 rose 1% during February-Value and large caps outperformed-The Australian 10-year bond yield rose 79 b...

Source: Voronin76,Shutterstock Summary World-leading regenerative medicine company Orthocell revealed that CelGro® Dental was included on the Australian Prostheses List. Additional antiviral testing proved that Starpharma’s antiviral...

Strong performing ASX healthcare shares came few and far between in February. The S&P/ASX Health Care Index (ASX: XHJ) was down 3% for the month, compared to the 1% increase in the ASX 200.   From respiratory devices, vaccine producers...

The Starpharma Holdings Limited (ASX: SPL) share price is in the red today, slipping 0.47% at the time of writing to $2.13. The biotechnology company develops new pharmaceutical and medical products based on proprietary polymers called den...

Source: Shutterstock Summary Pharmaceutical and medical products manufacturer Starpharma achieved multiple product development milestones during the challenging first half of 2021. The Company has completed the development of VIRALEZE...

Just because we have vaccines, doesn’t meant we can’t fight off this virus in other ways. Which is precisely what Starpharma Holdings Ltd [ASX:SPL] has been doing. And today the stock is trading 6.36% higher thanks to their ongoing fight.....

Source:Sutterstock Summary ASX 300-listed global biopharmaceutical company Starpharma has successfully registered its antiviral nasal spray in Europe, including the UK. The European launch of the nasal spray is on track and anticipate...

The Starpharma Holdings Limited (ASX: SPL) share price has been a very strong performer on Tuesday. At one stage today, the dendrimer products developer’s shares were up as much as 13% to $2.49. When the Starpharma share price hit that lev...

23 Feb 2021 - Pharmaceutical developer Starpharma (ASX:SPL) has received EU approval for the company’s antiviral nasal spray Viraleze.

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to continue its losing streak. The benchmark index is currently down slightly at 6,773 points. Four ASX shares that have not let that hold them back are listed below....

Starpharma (ASX:SPL) says it has received confirmation that the VIRALEZE antiviral nasal spray has been successfully registered for sale in Europe and the UK.

Australian pharmaceutical company Starpharma's (ASX: SPL) anti-COVID nasal spray VIRALEZE has been approved for sale in Europe and the UK today, and is now on track to launch next month. Shares in SPL have spiked on the announcement, up m...

The S&P/ASX 200 Index (ASX: XJO) has started the week strongly and is racing higher. In afternoon trade, the benchmark index is up 0.9% to 6,868.2 points. Four ASX shares that have failed to follow the market higher today are listed be...

Summary ASX 300-listed global biopharmaceutical company Starpharma has signed a Research Agreement with MSD. Under this agreement, MSD will perform a preclinical research evaluation of dendrimer-based ADCs utilising proprietary DEP® te...

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a decline. At the time of writing, the benchmark index is down 0.2% to 6,836.4 points. Four ASX shares that are not letting that hold them back ar...

The Starpharma Holdings Limited (ASX: SPL) share price has continued its positive run on Friday and charged higher again. In fact, at the time of writing, the dendrimer products developer’s shares are up 4% to a record high of $2.13. This...

Summary ASX 300-listed Starpharma Holdings stated that AstraZeneca intends to expand the clinical program for AZD0466 with Starpharma’s DEP® technology. The Company is aware that the intention is to accelerate AZD0466 development to ob...

In late morning trade the S&P/ASX 200 Index (ASX: XJO) looks set to end its winning run. At the time of writing, the benchmark index is down 0.3% to 6,861.6 points. Four ASX shares that have not let that hold them back are listed below...

The Starpharma Holdings Limited (ASX: SPL) share price has been a very positive performer on Tuesday. At one stage today, the dendrimer product developer’s shares jumped 7.5% to hit a record high of $2.10. The Starpharma share price has si...

Melbourne-based Starpharma (ASX:SPL) says it is on target and ready to launch its 'Viraleze' nasal spray in the UK and other European countries in March.

The Starpharma Holdings Limited (ASX: SPL) share price has dipped slightly today after the company released its quarterly cashflow and activities report for the quarter ended 31 December 2020. Starpharma is a global biopharmaceutical compa...

Analysts at Bell Potter have been busy finding ASX shares from several industries that they believe are best placed to have a strong 2021. On this occasion, I’m going to look at the healthcare sector. Here are a couple of shares they rate...

If 2020 taught us anything, it was the importance of quality healthcare. The COVID-19 pandemic put unprecedented demand on global health services, with many providers rising to the challenge. Healthcare has long been seen as a defensive in...

Michael Gable is an expert guest commentator for the Finance News Network, presenting “Stock Watch” each week – covering stock tips and shares on the Australian market (ASX). This video is dated 4 January 2020.  Shares covered: (ASX:SPL), (...

Summary Starpharma receives regulatory approval for clinical study for its antiviral nasal spray VIRALEZE™. VIRALEZE™ is a preventive measure, and the European demand for it has been quite strong, considering its worsening situation T...

Starpharma Holdings Limited (ASX: SPL) shares are edging lower despite the company announcing a positive update on its Viraleze antiviral nasal spray. At the time of writing, the Starpharma share price is down by 0.65% cents to $1.53. What...

Summary Healthcare firms across the world are working like a Trojan to seek an effective treatment for COVID-19. Some ASX-listed healthcare stocks contributing in COVID-19 battle seem to hold the robust potential to do wonders over the...

The S&P/ASX 200 Index (ASX: XJO) has followed the lead of U.S. markets and is on course to end its winning streak. In afternoon trade, the benchmark index is down 0.6% to 6,688 points. Four shares that have not let that hold them back...

10 Dec 2020 - Starpharma (ASX:SPL) says their Covid-19 nasal spray Viraleze will soon be ready for market.

Summary ASX 300 healthcare player Stapharma Holdings is set to launch its COVID-19 nasal spray VIRALEZE™ in the first quarter CY21. The Company is also conducting a clinical trial in healthy subjects to be completed in Q1 CY21. The la...

The Starpharma Holdings Limited (ASX: SPL) share price has surged higher on Thursday following the release of a big announcement. At the time of writing, the biopharmaceutical company’s shares are up 15% to $1.50. What did Starpharma annou...

Shares in Starpharma (ASX: SPL) surged more than 17 per cent in morning trade after the company announced it was on track to bring its anti-COVID nasal spray to the market earlier than expected. With an EU regulatory dossier 90 per cent...

Shares in Starpharma (ASX: SPL) surged more than 17 per cent in morning trade after the company announced it was on track to bring its anti-COVID nasal spray to the market earlier than expected. With an EU regulatory dossier 90 per cent c...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Summary Starpharma Holdings’ new data on SPL7013 has shown potent antiviral activity against human RSV (Respiratory Syncytial Virus). The study suggested that the nasal spray, SPL7013 would be effective if used before and/or after virus...

The Starpharma Holdings Limited (ASX: SPL) share price has been a very positive performer on Thursday. At the time of writing, the dendrimer products developer’s shares are up 6% to $1.40. Why is the Starpharma share price racing higher? I...

Investor focus is firmly on life sciences companies in 2020. FNArena highlights six ASX-listed entities that have been viewed positively by analysts recently -This year's pandemic has put life sciences firmly on investors' radar-Mesoblast's...